title: Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole.
abstract: The clinical efficacy of aripiprazole in the treatment of psychosis relies on a partial agonism at D2 receptors. As the expression of this receptor differs physiologically between pre- and post-synaptic sites and is affected by pathological conditions or pharmacological treatments, it appears difficult to predict the clinical response to partial agonists. In addition, the response to this novel antipsychotic was shown to depend on the cell-line and the pathway analyzed, suggesting a functional selective profile at the D2 receptor. This study aims at examining the influence of receptor density and ionic environment on the pharmacological properties of aripiprazole. A cell line was developed in which the expression of the recombinant D2 receptor can be tightly manipulated using doxycycline and sodium butyrate. The potency and efficacy of aripiprazole and other reference D2 receptor ligands were examined in [35S]GTPγS binding assays, in buffers containing either NaCl or N-methyl-D-glucamine (NMDG) which is proposed to enhance G protein coupling. Increasing the density of D2 receptors considerably enhanced the [35S]GTPγS binding induced by dopamine and the full agonist NPA. In maximally induced cells, the agonist properties of the partial agonist (-)-3-PPP was revealed in a buffer containing NaCl, whereas the response to aripiprazole was not evidenced. Substituting NMDG for NaCl promoted the response to dopamine and (-)3-PPP and was proven efficient to reveal the partial agonist profile of aripiprazole. While NMDG substitution for NaCl strongly enhanced receptor-G protein coupling, these ionic manipulations are likely to influence receptor conformations, thereby modulating the activation of signaling pathways. Our data obtained with partial agonists acting at the D2 receptor suggest that these changes in the experimental conditions could contribute to reveal the functional selective profile of GPCR ligands. They also emphasize that the properties of functional selective ligands do not only depend on receptor density but also on the surrounding environment which likely differs between brain structures.
authors.affiliation: Institute of Neuroscience (Ions), Group of Neuropharmacology, Université Catholique de Louvain, Avenue Mounier 53, bte B1.53.02, B-1200 Brussels, Belgium.
authors.forename: Beryl
authors.initials: B
authors.lastname: Koener
authors.forename: Marylène C
authors.initials: MC
authors.lastname: Focant
authors.forename: Barbara
authors.initials: B
authors.lastname: Bosier
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Maloteaux
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Hermans
mesh_terms: D000818:Animals; D000068180:Aripiprazole; D054333:Drug Partial Agonism; D006367:HeLa Cells; D006801:Humans; D008024:Ligands; D051379:Mice; D010879:Piperazines / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D015363:Quinolones / Q000378:metabolism / Q000494:pharmacology*; D017448:Receptors, Dopamine D2 / Q000819:agonists* / Q000378:metabolism* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
chemical_list: D008024:Ligands; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; C113776:dopamine D2L receptor; D000068180:Aripiprazole